ARYx Therapeutics Inc
OTC:ARYX

Watchlist Manager
ARYx Therapeutics Inc Logo
ARYx Therapeutics Inc
OTC:ARYX
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: 33.5 USD

ARYx Therapeutics Inc
Investor Relations

ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
No Earnings Calls Available

Management

Contacts

Address
CALIFORNIA
Fremont
6300 Dumbarton Cir
Contacts
+15105852200.0